Literature DB >> 31767462

Updates on immunologic correlates of vaccine-induced protection.

Stanley A Plotkin1.   

Abstract

Correlates of protection (CoPs) are increasingly important in the development and licensure of vaccines. Although the study of CoPs was initially directed at identifying a single immune function that could explain vaccine efficacy, it has become increasingly clear that there are often multiple functions responsible for efficacy. This review is meant to supplement prior articles on the subject, illustrating both simple and complex CoPs.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Cell mediated immunity; Correlates

Year:  2019        PMID: 31767462     DOI: 10.1016/j.vaccine.2019.10.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  37 in total

Review 1.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

2.  Human influenza virus challenge identifies cellular correlates of protection for oral vaccination.

Authors:  David R McIlwain; Han Chen; Zainab Rahil; Neda Hajiakhoond Bidoki; Sizun Jiang; Zach Bjornson; Nikita S Kolhatkar; C Josefina Martinez; Brice Gaudillière; Julien Hedou; Nilanjan Mukherjee; Christian M Schürch; Angelica Trejo; Melton Affrime; Bonnie Bock; Kenneth Kim; David Liebowitz; Nima Aghaeepour; Sean N Tucker; Garry P Nolan
Journal:  Cell Host Microbe       Date:  2021-11-15       Impact factor: 21.023

3.  Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection.

Authors:  Romain Marlin; Mélanie Prague; Marie Alexandre; Severin Coleon; Nidhal Kahlaoui; Sylvain Cardinaud; Thibaut Naninck; Benoit Delache; Mathieu Surenaud; Mathilde Galhaut; Nathalie Dereuddre-Bosquet; Mariangela Cavarelli; Pauline Maisonnasse; Mireille Centlivre; Christine Lacabaratz; Aurelie Wiedemann; Sandra Zurawski; Gerard Zurawski; Olivier Schwartz; Rogier W Sanders; Roger Le Grand; Yves Levy; Rodolphe Thiébaut
Journal:  Elife       Date:  2022-07-08       Impact factor: 8.713

4.  Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.

Authors:  Jordan A Stinson; Archana V Boopathy; Brian M Cieslewicz; Yichen Zhang; Nickolas W Hartman; David P Miller; Matthew Dirckx; Brett L Hurst; E Bart Tarbet; Jonathan A Kluge; Kathryn M Kosuda
Journal:  Vaccine       Date:  2021-08-12       Impact factor: 4.169

5.  Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial.

Authors:  Hana M El Sahly; Lindsey R Baden; Brandon Essink; David Montefiori; Adrian McDermont; Richard Rupp; Michael Lewis; Shobha Swaminathan; Carl Griffin; Veronica Fragoso; Vicki E Miller; Bethany Girard; Yamuna D Paila; Weiping Deng; Joanne E Tomassini; Robert Paris; Florian Schödel; Rituparna Das; Allison August; Brett Leav; Jacqueline M Miller; Honghong Zhou; Rolando Pajon
Journal:  J Infect Dis       Date:  2022-05-10       Impact factor: 7.759

6.  Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron.

Authors:  Anne-Cathrine S Vogt; Gilles Augusto; Byron Martina; Xinyue Chang; Gheyath Nasrallah; Daniel E Speiser; Monique Vogel; Martin F Bachmann; Mona O Mohsen
Journal:  Vaccines (Basel)       Date:  2022-05-09

7.  Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism.

Authors:  Martin F Bachmann; Mona O Mohsen; Daniel E Speiser
Journal:  NPJ Vaccines       Date:  2022-05-25       Impact factor: 9.399

8.  Targeted Amino Acid Substitution Overcomes Scale-Up Challenges with the Human C5a-Derived Decapeptide Immunostimulant EP67.

Authors:  Abdulraman M Alshammari; D David Smith; Jake Parriott; Jason P Stewart; Stephen M Curran; Russell J McCulloh; Peter A Barry; Smita S Iyer; Nicholas Palermo; Joy A Phillips; Yuxiang Dong; Donald R Ronning; Jonathan L Vennerstrom; Sam D Sanderson; Joseph A Vetro
Journal:  ACS Infect Dis       Date:  2020-04-13       Impact factor: 5.084

Review 9.  Looking beyond COVID-19 vaccine phase 3 trials.

Authors:  Jerome H Kim; Florian Marks; John D Clemens
Journal:  Nat Med       Date:  2021-01-19       Impact factor: 53.440

10.  Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.

Authors:  Carla S Walti; Elizabeth M Krantz; Joyce Maalouf; Jim Boonyaratanakornkit; Jacob Keane-Candib; Laurel Joncas-Schronce; Terry Stevens-Ayers; Sayan Dasgupta; Justin J Taylor; Alexandre V Hirayama; Merav Bar; Rebecca A Gardner; Andrew J Cowan; Damian J Green; Michael J Boeckh; David G Maloney; Cameron J Turtle; Joshua A Hill
Journal:  JCI Insight       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.